Imagion Biosystems secures nanoparticle manufacturer

Company News

by Jessica Amir

Imagion Biosystems (ASX:IBX), which provides nanomagetic detection for cancer and other diseases, has contracted a nanoparticle manufacturer to produce its first formulations for clinical breast cancer studies.

The company entered into an agreement with a Dutch firm, ChemConnection BV, to produce and supply formulations for the company’s HER2 cancer test.

As part of the agreement the manufacturing organisation will establish procedures for Imagion’s MagSense technology, with safety toxicology studies to commence in the first quarter of next year.

The technology uses bio-safe nanoparticles to locate, tag and characterise cancers and tumours in their early stages.

The collaboration will allow the company to conduct its first human test next year.

Shares in Imagion Biosystems (ASX:IBX) are trading flat at 13.5 cents.
 

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.